Suppr超能文献

化疗联合替雷利珠单抗治疗肺鳞状细胞癌后肺动脉假性动脉瘤致大量咯血:一例报告

Pulmonary artery pseudoaneurysm-induced massive hemoptysis after chemotherapy combined with tislelizumab for lung squamous cell carcinoma: a case report.

作者信息

Yang Xue-Jiao, Wu Yong-Juan, Wang Jing-Zhong, Zheng Yu-Lan, Li Xiao-Qi

机构信息

Department of Respiratory and Critical Care Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.

Department of Interventional Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.

出版信息

Front Med (Lausanne). 2025 Apr 3;12:1524248. doi: 10.3389/fmed.2025.1524248. eCollection 2025.

Abstract

Lung squamous cell carcinoma (SCC) is a subtype of non-small cell lung cancer with high incidence and mortality rates. While chemotherapy and immune checkpoint inhibitors (ICIs) have become crucial treatment options for SCC, these may be associated with unforeseen complications. Here, we present a 65-year-old male of hemoptysis caused by a pulmonary artery pseudoaneurysm (PAP) after chemotherapy combined with tislelizumab for lung SCC. After confirmation with angiography, successful embolization was performed to occlude the pseudoaneurysm and proximal artery. To our knowledge, this is the first reported case of PAP formation after chemotherapy combined with tislelizumab for lung SCC.

摘要

肺鳞状细胞癌(SCC)是一种发病率和死亡率都很高的非小细胞肺癌亚型。虽然化疗和免疫检查点抑制剂(ICIs)已成为SCC的关键治疗选择,但这些治疗可能会带来一些意想不到的并发症。在此,我们报告一例65岁男性,在接受化疗联合替雷利珠单抗治疗肺SCC后,因肺动脉假性动脉瘤(PAP)导致咯血。经血管造影确认后,成功进行了栓塞术以闭塞假性动脉瘤和近端动脉。据我们所知,这是首例关于化疗联合替雷利珠单抗治疗肺SCC后发生PAP的报道病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e8f/12003278/7fa1e9eb8de5/fmed-12-1524248-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验